Teduglutide — Membership Pricing
Teduglutide is not confirmed for no-additional-cost pricing. Membership pricing may be available; confirm the price with the dispensing pharmacy.
Teduglutide Pricing
| Pricing type | Price |
|---|---|
| TheDrugClub | Membership pricing may be available |
| Typical Retail | $57.00 |
Membership pricing may be available; confirm the price with the dispensing pharmacy.
About Teduglutide
Teduglutide is a prescription medication. Ask your doctor if Teduglutide is right for you.
How to Check Teduglutide Pricing
- Join TheDrugClub for $19.95/month
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available membership pricing
Teduglutide at Participating Pharmacies
- CVS Pharmacy
- Walgreens
- Walmart Pharmacy
- Rite Aid
- Kroger Pharmacy
- Costco Pharmacy
- Albertsons
- Safeway
- Publix Pharmacy
- H-E-B Pharmacy
Pharmacy participation and fulfillment options vary. Present your membership card and confirm current pricing before filling.
Other medications in Digestive Health
About Teduglutide
Teduglutide is a vital medication specifically designed for individuals living with Short Bowel Syndrome (SBS), helping to improve nutrient absorption and reduce the need for parenteral support. At TheDrugClub, we recognize the substantial financial burden that specialized treatments can impose. Our membership program is dedicated to providing significant savings on crucial prescriptions like Teduglutide, aiming to make your essential healthcare more accessible and affordable.
The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.
What Teduglutide is approved for (FDA label)
GATTEX ® is indicated for the treatment of adults and pediatric patients 1 year of age and older with Short Bowel Syndrome (SBS) who are dependent on parenteral support . GATTEX ® is a glucagon-like peptide-2 (GLP-2) analog indicated for the treatment of adults and pediatric patients 1 year of age and older with Short Bowel Syndrome (SBS) who are dependent on parenteral support. ( 1 )
Source: Read the full FDA label on DailyMed. Label effective date: September 5, 2025.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Dosage forms and strengths for Teduglutide (FDA label)
For Injection: 5 mg teduglutide as a white lyophilized powder for reconstitution in a single-dose vial supplied with 0.5 mL Sterile Water for Injection in a single-dose prefilled syringe. For injection: 5 mg teduglutide in a single-dose vial supplied with 0.5 mL Sterile Water for Injection in a single-dose prefilled syringe. ( 3 )
Source: FDA prescribing information (DailyMed). Set ID: 66b69c1e-b25c-44d3-b5ff-1c1de9a516fa. SPL document ID: 20ca0019-d3a4-4a8f-8dd4-67179d06e4dc. Label effective date: September 5, 2025. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Adverse reactions for Teduglutide (FDA label)
The following serious adverse reactions are described elsewhere in the labeling: Acceleration of Neoplastic Growth [see Warnings and Precautions ( 5.1 )] Intestinal Obstruction [see Warnings and Precautions ( 5.2 )] Biliary and Pancreatic Disease [see Warnings and Precautions ( 5.3 )] Fluid Imbalance and Fluid Overload [see Warnings and Precautions ( 5.4 )] Most common adverse reactions (≥10%) are: abdominal pain, nausea, upper respiratory tract infection, abdominal distension, injection site reaction, vomiting, fluid overload, and hypersensitivity. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Takeda Pharmaceuticals U.S.A., Inc. at 1-877-TAKEDA-7 (1-877-825-3327) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Adults Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed cannot be directly compared to rates in other clinical trials and may not reflect the rates observed in clinical practice.
Source: FDA prescribing information (DailyMed). Set ID: 66b69c1e-b25c-44d3-b5ff-1c1de9a516fa. SPL document ID: 20ca0019-d3a4-4a8f-8dd4-67179d06e4dc. Label effective date: September 5, 2025. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Contraindications for Teduglutide (FDA label)
None. None. ( 4 )
Source: FDA prescribing information (DailyMed). Set ID: 66b69c1e-b25c-44d3-b5ff-1c1de9a516fa. SPL document ID: 20ca0019-d3a4-4a8f-8dd4-67179d06e4dc. Label effective date: September 5, 2025. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Warnings and precautions for Teduglutide (FDA label)
Acceleration of Neoplastic Growth : In case of intestinal malignancy, discontinue GATTEX. The decision to continue GATTEX in patients with non-gastrointestinal malignancy should be made based on benefit risk considerations. ( 5.1 ) In adult patients, colonoscopy and upper GI endoscopy (or alternate imaging) is recommended after 1 year of treatment. Perform subsequent colonoscopies and upper GI endoscopes (or alternate imaging) no less frequently than every 5 years. ( 5.1 ) In pediatric patients, perform fecal occult blood testing annually. Colonoscopy/sigmoidoscopy is recommended after 1 year of treatment and every 5 years thereafter on treatment. Consider upper GI endoscopy (or alternate imaging) during treatment with GATTEX. ( 5.1 ) Intestinal Obstruction : In patients who develop intestinal or stomal obstruction, temporarily discontinue GATTEX pending further clinical evaluation and management. ( 5.2 ) Biliary and Pancreatic Disease : Obtain bilirubin, alkaline phosphatase, lipase, amylase every 6 months.
Source: FDA prescribing information (DailyMed). Set ID: 66b69c1e-b25c-44d3-b5ff-1c1de9a516fa. SPL document ID: 20ca0019-d3a4-4a8f-8dd4-67179d06e4dc. Label effective date: September 5, 2025. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Drug interactions for Teduglutide (FDA label)
7.1 Potential for Increased Absorption of Oral Medications Based upon the pharmacodynamic effect of GATTEX, there is a potential for increased absorption of concomitant oral medications. Altered mental status has been observed in patients taking GATTEX and benzodiazepines in the adult clinical studies [see Warnings and Precautions ( 5.5 )] . Monitor patients on concomitant oral drugs requiring titration or with a narrow therapeutic index for adverse reactions related to the concomitant drug while on GATTEX. The concomitant drug may require a reduction in dosage.
Source: FDA prescribing information (DailyMed). Set ID: 66b69c1e-b25c-44d3-b5ff-1c1de9a516fa. SPL document ID: 20ca0019-d3a4-4a8f-8dd4-67179d06e4dc. Label effective date: September 5, 2025. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.